This study aimed to evaluate the clinical efficacy of intravenous metoclopramide for the relief of pain and nausea among the emergency department patients with renal colic. Methods: Patients were randomised into three groups: tenoxicam (20 mg); tenoxicam (10 mg) plus metoclopramide (10 mg); and metoclopramide (10 mg). Changes in pain and nausea were examined at the 10th, 20th and 30th minute after treatment. The development of side effects would be recorded. After the 30th minute, the need for additional pain and nausea relief was evaluated. Results: Totally 80 patients were enrolled in each group. There was significant mean pain score difference as measured by visual analog scale (VAS) from 0 minute to 10th, 20th and 30th minute post-treatment for all treatment groups (p<0.001). There was no significant difference in mean VAS decrease from 0 minute to the 30th minute: tenoxicam group: 36 mm [95% confidence interval (CI) 28-43 mm] vs. tenoxicam plus metoclopramide: 45 mm (95% CI 38-52 mm) vs. metoclopramide group: 37 mm (95% CI 30-45 mm) (p=0.163). Similarly, no significant differences in mean nausea scores between the three groups were demonstrated at the 10th, 20th and 30th minute after treatment (p=0.236, 0.330 and 0.652 respectively). After the 30th minute, 43 (53%) patients needed additional pain relieving agent in the tenoxicam group compared to 27 (33%) patients in the tenoxicammetoclopramide group and 33 (41%) patients in the metoclopramide group (p=0.030). No significant adverse drug reaction events were encountered. Conclusion: Metoclopramide is as effective as tenoxicam to treat pain and nausea for patients with renal colic in the emergency department. (Hong Kong j.emerg.med. 2015;22:93-99) 
Introduction
Renal colic (RC) is the most common and most painful case disease diagnosed and treated in emergency department (ED). 1, 2 The risk of RC attack during a person's lifespan is 1-10%. The risk of reoccurrence in a five-year period is 50%. [1] [2] [3] [4] [5] In the ED, the elimination of pain, and nausea is prioritised along with diagnosis verification and detection of any complications that require urgent medical intervention. In recent years, the understanding of the pathophysiology of RC has led to the emergence of new studies on many pharmacological agents and methods. Additionally, the effectiveness of many pain relievers has been verified. Treatment is often performed by titrated opiate analgesics and/or slow-acting nonsteroidal anti-inflammatory drugs (NSAIDs). 1, [3] [4] [5] [6] However, alternative agents are still studied due to NSAIDs' and opiate analgesics' side effects and contraindications.
Searching the literature for studies describing the efficacy of metoclopramide, particularly on pain, using the keywords "vomiting", "ureteral colic", "urolithiasis", "renal colic" and "metoclopramide" revealed the two clinical studies 7, 8 and one case report 9 have been published since 1976. These studies suggested that metoclopramide might be an alternative in the treatment of pain due to RC. 7, 8 However, the clinical applicability of these studies were limited either by the small sample size and/or study methodology.
The aim of this study was to study the usefulness of metoclopramide on relieving pain in addition to nausea sensation among renal colic patients; and to compare it to the traditional medical treatment options.
Methods

Study patients
The study was conducted between April 2008 and February 2009. This single-institutional, prospective, randomised, double-blind clinical study was performed in a research university hospital emergency department serving approximately 40000 patients annually. The study was approved by the university ethics committee. All participants were informed and provided written consent. Adults (18 to 65 years) with colicky flank pain were eligible for inclusion in the study. Neither dysuria nor change of urine colour was used as an inclusion or exclusion criteria. Participants were required to have a clinical diagnosis of suspected renal colic. They were also required to have a complete urine analysis or radiography, ultrasonography or computed tomography (CT) if needed for the diagnosis. Prior to study enrollment, each patient agreed to participate by signing a "patient information form" and a "patient consent form". Exclusion criteria included non-colicky pain; known allergy to metoclopramide and tenoxicam; documented (known or suspected) peptic ulcer or gastrointestinal haemorrhage; known kidney failure; having only one kidney; use of pain reliever within 12 hours of ED presentation; pregnancy or breast feeding; evidence of distracting pain (such as fracture or burns); a pain diagnosis other than RC (such as acute appendicitis); and any additional emergency clinical condition. Vomiting and nausea were not used as inclusion or exclusion criteria. Keywords: Colicky pain, emergency medicine, human, non-steroidal anti-inflammatory agents and a designated nurse who would not take part in the clinical stage of the study put into a sack 80 pieces of paper on which the number one was written, 80 pieces of paper with the number two, and 80 pieces of paper with the number three. They prepared a list on which numbers from 1 to 240 were written. The pieces of paper with numbers, drawn randomly from the sack, were written across the corresponding number in the list. The list was kept by those who drew the numbers. The drugs were prepared by the same nurse who would not take part in the clinical stage of the study, and she also numbered the drugs. When patients suitable for the study visited the clinic, the doctors or the nurses, who participated in the clinical stage of the study, administered the drugs from 1 to 240. The groups were as follows: Group I: 2 mL injector 20 mg tenoxicam IV + 100 mL normal saline (NS), Group II: 2 mL injector 20 mg tenoxicam IV + 100 mL NS with 10 mg metoclopramide and Group III: 2 mL injector with NS + 100 mL NS with 10 mg metoclopramide.
Protocol and measured variables
A bundle consisting of one syringe and 100 mL of normal saline was prepared for each group and marked with each group's number. Because of the yellow colour of tenoxicam, one of the agents used in the study, the syringes were covered with plaster before the application.
Before receiving the study drug, subjects reported nausea and pain intensity on a 100 mm visual analogue scale (VAS) (bounded by "no pain/nausea" and "the worst pain/nausea"). Patients were given the drug in a double-blinded fashion by the doctor or the nurses responsible for the treatment.
The first agent was given to each patient as a slow bolus injection followed by a 5-minute infusion of the second agent (100 mL). The onset of treatment was recorded as 0 minute. At 10, 20 and 30 minute after drug administration, the intensity of nausea/pain were recorded via VAS. Patients were blinded to their previous reports.
After 30 minutes, patients with continuous complaints of vomiting and pain requiring additional treatment were given an antiemetic granisetron hydrchloride for vomiting. They also were given an antispasmodic agent or opiate analgesic for the pain as relevant for their clinical status. Additional treatment suggestions, which were used after 30 minutes in cases of necessity, were recorded on the patient information forms. All patients were discharged after the diagnosis and treatment period at the ED and were referred to a urology outpatient clinic. As we did not use gold-standard CT scan for each patient at ED for diagnosis, evaluations in the outpatient clinic were taken into consideration to support the diagnosis. One month after discharge, their files were reexamined.
The mean differences in the VAS scores were taken as the primary efficacy outcome.
Statistical analysis
All statistical analyses were performed using SPSS version 13.0 for Windows. For the purpose of this study, we progressed through a scale of values between 10 to 100 and assumed that α error=0.05, β error=0.20 (power 1-β=0.80), and based on the study of Hadenbro and Olson, 8 we defined standard error as 30 and mean difference as 20. Accordingly, we defined the number of members for each group as n=70-80. Average values for the variables, such as scale values, were calculated as ± standard deviation (±SD). The consistency of the measurement variables with the normal distribution was tested. Statistical differences were determined in numerable variables such as gender distribution by using the Chi-square test. Analysis of variance (ANOVA) was used in comparing age distribution, VAS scores, the mean differences of pain and nausea. The evaluations before and after the acquired variables from the groups at 0th, 10th, 20th and 30th minute were considered as dependent samples, thus the paired t test was used. In cases not compatible with normal distribution, the Wilcoxon Signed Rank Test was used. If the p-value was less than 0.05 (p<0.05), the relationship was considered to be significant.
Results
A total of 397 patients presenting with complaints of urinary tract stone disease (according to the ICD-10 coding system) were evaluated for the study. Of these, 240 patients were enrolled in the study consecutively and divided in three groups composed of 80 patients each (Figure 1) . No difference between the demographic data of the patients and the distribution of VAS pain and nausea scores to the groups at the time of presentation to the ED was observed (Table 1 ). In all groups at 0 minute, the mean VAS nausea and pain scores were 20.26 mm [95% confidence interval (CI)=16-23 mm] and 68.90 mm (95% CI=65-72 mm), respectively (p=0.784 and p=0.768, respectively). At minute 0, VAS nausea score was zero for 8, 5 and 11 patients in Groups I, II and III respectively. At minute 0, two patients whose VAS pain scores were 5 (the minimum value in the study group) were in Group I and II. In the other patients the VAS score was over 10 mm.
When we analysed all the patients included in the study as a whole and when we analyse them separately in their designated groups from the 0 minute to 10th, 20th and 30th minute of post-treatment, a significant mean reduction among VAS pain intensity scores was found (for each p<0.010) ( Table 2 ). Analysis of variance (ANOVA) was used in comparing VAS scores.
No significant differences in VAS were detected between the groups at 10th and 30th post treatment (p=0.529 and p=0.163, respectively). However, significant difference was observed (p=0.018) when the mean difference in VAS pain score between the 0 minute and 20th post-treatment minute was evaluated. Reduction in pain in Group II was more than the reduction in Group I (p=0.009) and Group III (p=0.019). No difference between Group I and Group III was found (p=0.755). In general, Group II had a trend of larger reduction of VAS than the other 2 groups (Table 3) .
When the mean differences in VAS nausea score between 0 minute and post-treatment 10th, 20th and 30th minute were evaluated, we observed a decrease in nausea levels in all groups. No significant differences were revealed in the mean differences in VAS nausea scores between the groups at 10th, 20th and 30th minute post treatment (p=0.236 vs.0.330 vs. 0.652, respectively) ( Table 4 ). At the 30th minute, no additional nausea relieving agent was used in Group II. Thus, the Kolmogorov test was used to assess the necessity of additional nausea relieving agent, and a significant difference between the groups was observed (p=0.020). In the next step we conducted advanced analysis and it revealed that the difference originated from Group I (tenoxicam group), and need for additional nausea relieving agent in this group is greater than the other groups. No significant difference was observed between Group II (tenoxicam plus metoclopramide group) and Group III (metoclopramide group).
At the 30th minute, 43 patients (53.7%) in Group I, 27 patients (33.7%) in Group II and 33 patients (41.2%) in Group III needed additional pain reliever (p=0.036). The following advanced analysis showed that the difference originated from Group I (tenoxicam group) and the need for additional pain relieving agent in this group was more than the other groups. No significant difference was found between Group II (tenoxicam plus metoclopramide group) and Group III (metoclopramide group). We could not do analysis on the occurrence of side effect/adverse drug reaction because no event was encountered during the treatments.
Discussion
For stable ED patients presenting with colicky pain, pain management is the first priority following the acquisition of the patient's history and a detailed physical examination.
Treatment is often performed by titrated opiate analgesics and/or slow-acting nonsteroidal antiinflammator y dr ugs (NSAIDs). 1, [3] [4] [5] [6] However, alternative agents were required due to side effects and contraindications to NSAIDs and opiate analgesics. Alertnative agents being studied included: α-adrenergic blocker tamsulosin, intranasal desmopressin, isosorbide dinitrate and nifedipine. [10] [11] [12] [13] [14] [15] [16] [17] So far, there are only few studies in literature focusing on the effectiveness of anti-cholinergic medication used alone or in addition to NSAIDs or opiates for the treatment of RC.
In 1979, Schelin demonstrated that the pain relieving effect of metoclopramide in RC in a four-case study, acting through central inhibition of nausea and prochinetic efficacy in gastrointestinal system smooth muscles. 9 Berman and Firlit supported Schelin's conclusion with an in vitro study assessing the efficacy of metoclopramide on ureteral motility. 18 Hadenbro and Olsson conducted a double-blind study with 39 patients diagnosed with RC after clinical and radiological evaluations. In their study, patients were randomly divided between metoclopramide and Spasmofen (0.15 mg metiloscopolamin nitrate, 20 mg papaverin hydrochloride, 6.6 mg morphine hydrochloride, 3 mg noscapin hydrochloride, and 0.4 mg codeine chloride) groups; no difference in reduction of pain intensity was revealed. 7 Müller compared 1 mL morphatropin (0.5 mg atropine in 1 mL and 20 mg morphine HCl) and 20 mg metoclopramide groups in 21 patients diagnosed with acute ureterolithiasis in a prospective, randomised and double blind study. They observed equal pain relieving effect in both groups. No side effect was detected in the metoclopramide group. 8 As a result, several theories on the effect of metoclopramide on the urinary system were developed: 1) a direct prokinetic effect on smooth muscle; 2) a decrease in dopaminergic effect; 3) an increase in cholinergic effect; and 4) development of local anesthetic efficacy. 17 Despite of these results, small sample size recuited in these studies weakened the validity of the current data on metoclopramide. Our study was superior to them in terms of sample size and methodology.
The Guidelines on Urolithiasis published by the European Association of Urology has recommended the use of diclofenac sodium, an NSAID, as the first choice for pain management of RC (evidence level 1b). 19 Thus, we compared metoclopramide with NSAIDs in our study. Tenoxicam was selected from the NSAID group because it can be used intravenously. Our results were comparable with the those of studies by Hadenbro and Olsson and Müller et al. 7, 8 Noteable, we demonstrated a more clear benefits of metoclopramide in the pain management phase of RC: less patients treated with metoclopramide would need an additional pain relieving agent or additional nausea relieving agent than those treated with NSAID alone.
Limitations
This study had several limitations. Patients receiving opiates before treatment (an approved treatment for acute RC pain) could have been included. The evaluations were made within the first 30 minutes only after drug administration at the ED. After 30 minutes, the effects of different regimes were not evaluated. The diagnosis of RC in our study population was made by different imaging modalities.
Conclusions
Metoclopramide can be as effective as tenoxicam as single agent for the acute treatment of pain and nausea for patient suffering from renal colic. Metoclopramide can be an alternative treatment, especially for those patients with contraindications to use non-steroidal anti-inflammatory drug. Patients treated with tenoxicam alone have a higher chance of requiring an additional nausea relieving agent than those treated with combined treatment or metoclopramide alone.
